Last updated: June 10, 2023
Sponsor: Alexandria University
Overall Status: Active - Recruiting
Phase
4
Condition
Chronic Renal Anemia
Anemia
Treatment
Lactoferrin
Ferrous Glycine Sulfate
Clinical Study ID
NCT05900635
0107174
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Males and Females aged ≥ 18 years old
- Patients with eGFR ≥30 and ≤60 mL/min/1.73m2.
- Absolute iron deficiency anemia (Hgb <10g/dL, serum ferritin <300ng/ml and TransferrinSaturation < 30% )
Exclusion
Exclusion Criteria:
- Patients on intermittent hemodialysis (IHD)
- Patients with any known cause of anemia other than iron deficiency or CKD (e.g.,sickle cell anemia)
- Patients who received EPO 4 weeks ago
- Patients who received IV Iron 8 weeks ago
- Patients who received blood Transfusion 8 weeks ago
- Current history of GI bleeding
- Malignancy history
- Pregnancy or lactation in female participants
- Patients non-adherent to at least 80% of the regimen
Study Design
Total Participants: 60
Treatment Group(s): 2
Primary Treatment: Lactoferrin
Phase: 4
Study Start date:
October 01, 2022
Estimated Completion Date:
September 30, 2023
Study Description
Connect with a study center
Kidney and Urology Center
Alexandria, 21548
EgyptActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.